Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease

被引：23

作者：

Valldeoriola, Francesc ^{[1
]}

Grandas, Francisco ^{[2
]}

Santos-Garcia, Diego ^{[3
]}

Regidor, Ignacio ^{[4
]}

Catalan, Maria Jose ^{[5
]}

Arbelo, Jose Matias ^{[6
]}

Puente, Victor ^{[7
]}

Mir, Pablo ^{[8
,9
]}

Parra, Juan Carlos ^{[10
]}

机构：

[1] Hosp Clin Barcelona, Dept Neurol, Movement Disorders Unit, Carrer Villarroel 170, Barcelona, Spain

[2] Hosp Gen Univ Gregorio Maranon, Dept Neurol, Calle Doctor Esquerdo 46, Madrid 28007, Spain

[3] Complejo Hosp Univ Ferrol, Hosp Arquitecto Marcide, Dept Internal Med, Neurol Sect, Av Residencia S-N, Ferrol 15405, A Coruna, Spain

[4] Hosp Univ Ramon y Cajal, Funct Neurosugery Unit, Carretera Colmenar Km 9,100, Madrid 28034, Spain

[5] Hosp Clin San Carlos, Dept Neurol, Prof Martin Lagos S-N, Madrid 28040, Spain

[6] Hosp Univ Insular Gran Canaria, Dept Neurol, Ave Maritima Sur S-N, Las Palmas Gran De Canar 35016, Spain

[7] Univ Autonoma Barcelona, Movement Disorders Unit, Dept Neurol, Hosp Mar,Inst Municipal Invest Med, Parc Salut Mar,Passeig Maritim 25-29, Barcelona 08003, Spain

[8] Univ Seville, Movement Disorders Unit, Dept Neurol, Hosp Univ Virgen del Rocio,Inst Biomed Sevilla,CS, Av Manuel Siurot S-N, Seville 41013, Spain

[9] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Campus Cantoblanco, Madrid 28049, Spain

[10] AbbVie Spain SLU, Ave Burgos 91, Madrid 28050, Spain

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2016年 / 6卷 / 04期

关键词：

dyskinesia; levodopa-carbidopa intestinal gel; nonmotor symptoms; 'off' time; Parkinson's disease;

D O I：

10.2217/nmt-2016-0021

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Aim: To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease. Patients & methods: This was an observational, multicenter, cross-sectional, retrospective study. Results: Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively. Conclusion: This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.

引用

页码：289 / 298

页数：10

共 35 条

[1]

Abbruzzese G, 2012, FUNCT NEUROL, V27, P147

[2]

[Anonymous], 1976, ECDEU ASSESSMENT MAN

[3] Duodenal levoclopa infusion improves quality of life in advanced Parkinson's disease [J].

Antonini, A. ;

Mancini, F. ;

Canesi, M. ;

Zangaglia, R. ;

Isaias, I. U. ;

Manfredi, L. ;

Pacchetti, C. ;

Zibetti, M. ;

Natuzzi, F. ;

Lopiano, L. ;

Nappi, G. ;

Pezzoli, G. .

NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) :244-246

[4] Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes [J].

Antonini, Angelo ;

Yegin, Ashley ;

Preda, Cornelia ;

Bergmann, Lars ;

Poewe, Werner .

PARKINSONISM & RELATED DISORDERS, 2015, 21 (03) :231-235

[5] A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation [J].

Antonini, Angelo ;

Isaias, Ioannis U. ;

Rodolfi, Giorgia ;

Landi, Andrea ;

Natuzzi, Francesca ;

Siri, Chiara ;

Pezzoli, Gianni .

JOURNAL OF NEUROLOGY, 2011, 258 (04) :579-585

[6] Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson's Disease [J].

Antonini, Angelo ;

Chaudhuri, K. Ray ;

Martinez-Martin, Pablo ;

Odin, Per .

CNS DRUGS, 2010, 24 (02) :119-129

[7] INTRADUODENAL INFUSION OF A WATER-BASED LEVODOPA DISPERSION FOR OPTIMIZATION OF THE THERAPEUTIC EFFECT IN SEVERE PARKINSONS-DISEASE [J].

BREDBERG, E ;

NILSSON, D ;

JOHANSSON, K ;

AQUILONIUS, SM ;

JOHNELS, B ;

NYSTROM, C ;

PAALZOW, L .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (02) :117-122

[8] Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease [J].

Calandrella, Daniela ;

Romito, Luigi M. ;

Elia, Antonio E. ;

Del Sorbo, Francesca ;

Bagella, Caterina F. ;

Falsitta, Massimo ;

Albanese, Alberto .

NEUROLOGY, 2015, 84 (16) :1669-1672

[9] Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? [J].

Chaudhuri, K. Ray ;

Rizos, Alexandra ;

Sethi, Kapil D. .

JOURNAL OF NEURAL TRANSMISSION, 2013, 120 (09) :1305-1320

[10] The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study [J].

Chaudhuri, Kallol Ray ;

Martinez-Martin, Pablo ;

Brown, Richard G. ;

Sethi, Kapil ;

Stocchi, Fabrizio ;

Odin, Per ;

Ondo, William ;

Abe, Kazuo ;

MacPhee, Graeme ;

MacMahon, Doug ;

Barone, Paolo ;

Rabey, Martin ;

Forbes, Alison ;

Breen, Kieran ;

Tluk, Susanne ;

Naidu, Yogini ;

Olanow, Warren ;

Williams, Adrian J. ;

Thomas, Sue ;

Rye, David ;

Tsuboi, Yoshio ;

Hand, Annette ;

Schapira, Anthony H. V. .

MOVEMENT DISORDERS, 2007, 22 (13) :1901-1911

← 1 2 3 4 →